Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab With or Without Compound Qingdai Capsules in Moderate-to-Severe Plaque Psoriasis (Real-World Cohort)
ChiCTR2600126823Phase 4Not yet recruiting
- Sponsor
- Gong An County People's Hospital
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of secukinumab and Compound Qingdai Capsules in plaque psoriasis (2 arms), sponsored by Gong An County People's Hospital. Primary endpoint: Relapse cycle. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
secukinumabCompound Qingdai Capsules
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ChiCTR2600126823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126823.